NMN vs NR (Nicotinamide Riboside): Choosing the Right NAD+ Precursor
The Short Version
NR has a longer track record of published human clinical trials and FDA GRAS status through ChromaDex's Niagen. NMN is catching up fast with recent studies showing it effectively raises NAD+ levels in humans. Neither has proven long-term anti-aging benefits in people yet. If you want the more established safety profile, NR is the conservative pick. If you prefer the more direct NAD+ pathway and don't mind newer evidence, NMN is a reasonable choice.
Key Differences
| Factor | NMN | NR (Nicotinamide Riboside) |
|---|---|---|
| Pathway to NAD+ | NMN is converted to NAD+ by NMNAT enzymes — one enzymatic step from NAD+ | NR is converted to NMN by NRK1/2 enzymes, then NMN to NAD+ — two enzymatic steps from NAD+ |
| Molecular Size & Cell Entry | Larger molecule (334 Da) — debated whether it enters cells directly or must be converted to NR first via CD73 | Smaller molecule (255 Da) — enters cells via equilibrative nucleoside transporters |
| Human Clinical Evidence | Growing but newer — Yoshino et al. 2021 (n=25), Yi et al. 2023 (n=80), MASADA-NMN 2024 | More established — Martens et al. 2018 (n=24), Elysium NRPT trial 2017 (n=120), Dollerup et al. 2018 (n=40) |
| FDA Regulatory Status | Sold as a supplement but FDA initially challenged its dietary supplement status in 2022; situation has since evolved | GRAS (Generally Recognized as Safe) status through ChromaDex's Niagen since 2016 |
| NAD+ Elevation in Humans | Yoshino et al. 2021 showed 250mg/day raised blood NAD+ metabolites in overweight women (n=25) | Martens et al. 2018 showed 1000mg/day raised blood NAD+ by ~60% in healthy older adults (n=24) |
| Price per Effective Dose | Typically $1.00–$2.50/day for 250–500mg — wide range depending on brand and purity | Typically $1.50–$2.00/day for 300–1000mg Niagen — more standardized pricing |
Best For
People who want the most direct NAD+ precursor pathway and are comfortable with a newer evidence base
People who want the most direct NAD+ precursor pathway and are comfortable with a newer evidence base
Those interested in metabolic health
Yoshino et al. 2021 showed insulin sensitivity improvements
Individuals who prefer flexibility in dosing and sourcing, with multiple brands now offering third-party tested options
Individuals who prefer flexibility in dosing and sourcing, with multiple brands now offering third-party tested options
People who prioritize a longer human safety and efficacy track record
more published RCTs to date
Those who want FDA GRAS-status assurance through ChromaDex's Niagen ingredient
Those who want FDA GRAS-status assurance through ChromaDex's Niagen ingredient
Individuals focused on cardiovascular indicators
Martens et al. 2018 showed a blood pressure trend worth watching
Evidence Snapshot
Both NMN and NR raise NAD+ levels in humans — that much is clear from multiple trials. NR has been studied in more published human RCTs: Martens et al. (J Am Heart Assoc, 2018, n=24) showed a 60% NAD+ increase and blood pressure trends; Dollerup et al. (Am J Clin Nutr, 2018, n=40) found NR was safe and raised NAD+ but didn't improve insulin sensitivity in obese men; Dellinger et al. (NPJ Aging, 2017, n=120) confirmed NAD+ elevation with an NR combination product. NMN's human evidence is growing. Yoshino et al. (Science, 2021, n=25) is the landmark study showing metabolic benefits. Yi et al. (GeroScience, 2023, n=80) demonstrated NAD+ elevation and physical performance improvements. MASADA-NMN (2024) added further human safety data. The overall evidence level for both is moderate — they raise NAD+, but downstream health benefits in humans haven't been conclusively established in large, long-term trials.
Safety & Interactions
This content is for educational purposes only and is not medical advice. These statements have not been evaluated by the FDA. Always consult your healthcare provider before starting any supplement.